INTRODUCTION
G out is the most common cause of infl ammatory arthritis in men [1] . Approximately 33% of gout patients have type 2 diabetes (T2D). Hyperuricemia and gout are closely related to the presence of metabolic syndrome. It is well documented that hyperuricemia precedes hyperinsulinemia and it has been determined as a separate risk factor for the development of hyperinsulinemia and T2D [2] . There is evidence that gout and T2D share common risk alleles [3, 4] . In 1969 Boyle and McKiddie demonstrated for the fi rst time that blood glucose and plasma insulin increased signifi cantly in gout patients after glucose loading [5] . In 2006 the Finnish Diabetes Prevention Study reported that in middle-age high risk individuals, serum uric acid and its fl uctuations are connected to the development of T2D [6] . In 2008 Choi analyzed the data of men with high cardiovascular risk in the Multiple Risk Factor Intervention Trial (MRFIT) and found that men with gout were at a higher risk of developing T2D. This relationship did not depend on the presence of known risk factors, but they should be treated aggressively for gout [7] . Later, Kim in 2015, and Rho in 2016 reaffi rmed the high risk of developing T2D in subjects with gout [8, 9] . The latest data in the fi eld show that the presence of diabetes may prevent from development of gouty arthritis. Higher levels of glycated hemoglobin protect from symptoms of gout infl ammation, which could be due to the uricosuric eff ect of glucose [10] . The risk factors for both diseases are similar and the pathogenic pathways are also shared [11] . There have been reports that urate-lowering therapy might reduce the risk for T2D [12] .
Considering this well documented links between the phenotypes, we decided to look whether there might be a diff erence in the cardiovascular risk, calculated by the Framingham Risk Score (FRS) and additionally assessed by complex multimodal ultrasonography, in patients with asymptomatic hyperuricemia and gout with or without T2D. By ultrasound we measured the left atrial size (LA), intima-media thickness (IMT) and common carotid artery resistive index (CC-ARI) − parameters which are known as independent predictors of cardiovascular risk [13, 14] . In addition, we investigated changes in the end-diastolic volume index (EDVi), end-systolic volume index (ESVi), stroke volume index (SVi), ejection fraction (EF), fractional shortening (FS) and left ventricular mass index (LVMi).
METHODS
This is a single center cross-sectional study, including 52 asymptomatic patients with hyperuricemia and 149 patients with gout (their clinical data are summarized in Table 1 ). Consecutive patients between June 2013 and May 2016 were included. Subjects with asymptomatic hyperuricemia were outpatients, while patients with gout were hospitalized at the University Rheumatology Clinic Sv. Ivan Rilski in Sofi a. Indications for hospitalization were either gout attacks or assessment for further treatment. All the patients with gout fulfi lled the 1977 ACR criteria [15] . The subcutaneous tophi on physical examination were typical Gouty tophi. Subjects with asymptomatic hyperuricemia had serum uric acid above the normal range and no history of gout fl are. The study protocol has been approved by the ethics committee of the institution. All participants gave informed consent in accordance with the Declaration of Helsinki.
The Framingham Risk Score (FRS) was calculated by an internet-based formula. It assessed the individual 10-year risk of developing cardiovascular disease incorporating 7 items such as sex, age, total cholesterol, high density lipoprotein cholesterol, smoking, the systolic blood pressure, and the presence of treated and untreated arterial hypertension. According to this scoring system, individuals with low 10 year-risk have < 10% coronary heart disease risk, those with intermediate risk − 10-20% and those with high risk − ≥ 20% [16, 17] . The clinical and laboratory assessments included current smoking status, presence of arterial hypertension defi ned as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or use of antihypertensive medication; diabetes mellitus, based on the current examination and/or documented use of insulin and/or oral hypoglycemic agents; dyslipidemia, based on elevated fasting lipid levels or low HDL and/or documented use of lipidlowering agents; reduced glomerular fi ltration rate defi ned as eGFR < 90 ml/min by the Cockroft-Gault formula, chronic kidney failure (CKF) as defi ned in the K/DOQI 2002 guidelines [18] . The additional laboratory parameters included in the analysis were: Creactive protein (CRP), serum creatinine, blood urea nitrogen (BUN), serum uric acid and serum albumin concentrations. Patients were defi ned as having sustained a cardiovascular event if they had proven coronary artery disease, cerebrovascular disease and/ or peripheral artery disease [19] . The exclusion criteria were: history of malignancy, exacerbated cardiac or renal failure, dilatative or hypertrophic cardiomyopathy, severe valvulopathy, atrial fi brillation, arterial blood pressure > 140/90 mmHg and heart rate < 50 bpm or > 90 bpm during the ultrasonographic measurement.
Subjects underwent a multimodal ultrasound examination, performed by a single operator, who was unaware of the clinical data. From June 2013 till November 2015 the ultrasound examinations were carried out on an ALOKA-SSD-4000 device. Since November 2015 till May 2016 they were performed on a Philips HD 11 machine. The software of both devices had comparable characteristics.
Echocardiographic examinations were conducted according to the recommendations of the American Society of Echocardiography with a 2.5 MHz transducer phased array [20] . A minimum of three cardiac cycles were analyzed and averaged. From the parasternal long axis view, uniaxial anteriorposterior dimension of the left atrium (LA) was determined. End-diastolic volume index (EDVi), endsystolic volume index (ESVi), stroke volume index (SVi) and fractional shortening (FS) were recorded in 2-dimentionally guided M-mode. The Ejection fraction (EF) was calculated by the Teicholz method. The Left ventricular muscle mass was estimated by the Devereux formula. The carotid arteries were examined with a 10 MHz linear transducer with 5 MHz pulse Doppler frequency. The Intimamedia thickness (IMT) was bilaterally recorded in the far wall of the common carotid arteries 1-2 cm proximal to the bifurcation. The common carotid artery resistive index (CCARI) refl ects the rigidity and distensibility of the common carotid arteries. It was determined with a pulse Doppler probe volume of 3 mm and an orientation angle between 30° and 60°, and calculated as follows: [peak systolic velocity (CVp) -end-diastolic velocity (CVd)/ peak systolic velocity (CVp)] [14] . The mean values of the clinical, laboratory and ultrasound parameters were analyzed.
STATISTICS
Statistical analyses were done by using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). The means with SDs and percentages were calculated to describe the clinical and ultrasound characteristics of the patients. Intergroup comparisons were performed by One-Sample Kolmogorov-Smirnov, Shapiro-Wilk and Paired-Samples T-tests. Proportional diff erences were tested using the chi-square and Fisher's exact test. All tests were two tailed, and p values less than 0.05 were considered statistically signifi cant.
RESULTS
The characteristics of our patients' cohort are summarized in Table 1 . All examined patients in both subgroups were age-matched. There was a male preponderance in the gout group (p < 0.001). In the latter the level of hyperuricemia (p = 0.028), CRP (p = 0.022) and the number of smokers (p = 0.005) was higher. The remaining cardiovascular risk factors were equally distributed among the groups. According to the FRS, the cardiovascular risk was higher in subjects with gout than in asymptomatic hyperuricemia. Gout patients had an intermediate risk (mean ± SD; 14.60 ± 8.96%) while those with asymptomatic hyperuricemia were scored as having a low risk (mean ± SD; 5.69 ± 6.03%), ( Table 1 ). The proportion of hypertensive patients and individuals who had suff ered a cardiovascular event was larger in diabetic patients with asymptomatic hyperuricemia. Similarly, in the gout group the number of patients who had sustained a cardiovascular event was higher among individuals with T2D (Table 2 ).
In asymptomatic hyperuricemia the scores obtained by FRS were comparable between diabetic and nondiabetic patients (p = 0.580). However, subjects with T2D had larger LA (mean ± SD; 41.08 ± 4.64 mm vs 37.43 ± 5.71 mm, p = 0.023), thicker intima-media (mean ± SD; 0.88 ± 0.09 mm vs 0.77 ± 0.18 mm, p = 0.004) and higher CCARI (mean ± SD; 0.71 ± 0.03 vs 0.68 ± 0.06, p = 0.036), (Fig. 1 a, b, i, j) . No difference was registered in the mean values of EDVi, ESVi, SVi, EF, FS and LVMI (Fig. 1 c, d , e, f, g, h) between diabetic and non-diabetic individuals in this group. Likewise, among diabetic and non-diabetic individuals suff ering from gout, there was no diff erence in the mean values of the FRS (p = 0.849), but EF of the heart was lower in those with diabetes (p = 0.014), (Fig. 2 a, f) . Among the diabetic and nondiabetic subjects with gout, the means of LA, EDVi, ESVi, SVi, EF, FS, LVMI, IMT and CCARI were similar (Fig. 2 b, c, d , e, g, h, i, j). When the gouty tophi group was examined separately the values of FRS were similar (Fig. 3 a) . We observed that LA was larger in the cases with T2D (mean ± SD; 45.41 ± 5.62 mm vs 39.77 ± 5.78 mm, p = 0.014), (fi g 3 b). In this subgroup diabetics also had lower EDVi, ESVi, EF, FS and greater LVMI (Fig. 3 c, d, f, g, h) . As to the parameters of the carotid arteries, there was no difference between diabetic and non-diabetic subjects with tophi, (Fig. 3 i, j) . Table 2 . Serum levels of uric acid, use of diuretics and the distribution of conventional cardiovascular risk factors in patients with T2D and non-diabetic patients are displayed 
DISCUSSION
In the present study, we found that the mean values of the FRS among patients with and without T2D in the groups with asymptomatic hyperuricemia, gout and gouty tophi were not diff erent. Involvement of the heart and common carotid arteries was more pronounced in individuals with T2D. In the group with asymptomatic hyperuricemia, the diabetic patients had larger LA and more advanced atherosclerotic and arteriosclerotic common carotid arteries changes. Subjects with gout and diabetes had a signifi cantly lower systolic function in comparison to gout subjects without diabetes. These results led us to investigate the alterations in individuals with gouty tophi, as tophi maintain a chronic infl ammatory process even during the intercritical phase [21] . We found that in individuals with gouty tophi and diabetes the morphological and functional heart parameters were more severely aff ected than in those without diabetes.
Previous echocardiography studies have established that a large proportion of individuals with T2D have left ventricular hypertrophy, diastolic dysfunction, abnormally large left atriums and low EF [22] . Data from the literature also show that T2D and even the prediabetic state are independently associated with the presence of left ventricular hypertrophy [23] . On the other hand, evidence exists that gout and especially gouty tophi are linked to left ventricular diastolic dysfunction and left atrium volume enlargement [24] . As far as the carotid arteries are concerned, T2D leads to thicker intima-media, higher stiff ness of the arterial wall and development of atherosclerotic plaques [25, 26] . Similarly, hyperuricemia and gout are associated with greater thickness and stiff ness of the carotid arteries, as well as with a higher frequency of atherosclerotic plaques [27] [28] [29] .
Uric acid induces mitochondrial oxidative stress in the hepatocytes and may lead to development of fatty liver. All this may worsen the insulin resistance by reducing the bioavailability of nitric oxide (NO) [11] . There is evidence that maintaining low-grade infl ammation in gout patients unlocks the development of diabetes, with C-reactive protein (CRP), IL-6 and soluble adhesion molecules playing a major role. At the renal level, insulin increases the reabsorption of urate by activating URAT-1 and reducing its excretion [31] . Based on our fi ndings, we conclude that type 2 diabetes in combination with asymptomatic hyperuricemia, and especially with gouty tophi, creates a complex proatherogenic milieu with interlacing and mutually potentiating mechanisms. Further research is needed to elucidate these complex proatherogenic mechanisms.
In conclusion, we found no diff erence in the FRS between diabetics and non-diabetics in the examined groups, although by complex multimodal ultrasonography we could identify diff erences in the individual parameters of the heart and common carotid arteries. These results suggest that a more comprehensive approach is needed in the assessment of cardiovascular risk in type 2 diabetics with asymptomatic hyperuricemia and gouty tophi. Several limitations of our study deserve to be mentioned. This was a single centre cross-sectional study, laboratory parameters were measured at a fi xed point of time, and in asymptomatic hyperuricemia no additional imaging methods for detection of silent monosodium urate crystals were applied. Future studies should be able to surpass these limitations and give a more comprehensive picture of the cardiovascular risk profi le in type 2 diabetic patients with asymptomatic hyperuricemia and gout.
